Associate Director – Field Medical Affairs-Hematology
| Company | Regeneron Pharmaceuticals |
|---|---|
| Location | Kentucky, USA, Ohio, USA, Michigan, USA, United States |
| Salary | $173500 – $283100 |
| Type | Full-Time |
| Degrees | PharmD, PhD, MD |
| Experience Level | Senior, Expert or higher |
Requirements
- Terminal scientific degree (MD, PharmD, or PhD) required
- 8+ years of experience
- Minimum of 4 years experience within a Hematology/Oncology Medical Science Liaison function required
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines
Responsibilities
- Identifying and maintaining a list of medical/therapeutic area experts, investigator targets and associated plans of action
- Establishing, fostering, cultivating and maintaining relationships with KOLs in Hematological Malignancies
- Act as the primary clinical/scientific resource for information pertaining to disease state and our products ensuring awareness and understanding
- Participates in the development and management of company sponsored clinical trials
- Establishing scientific relationship with investigators and internal Medical Affairs, supporting investigator-initiated study (IIS) concept program
- Identifying relevant insights on research developments, treatment landscape to shape medical strategy
- Identifies gaps in research needs and creates opportunities by collaborating with potential and existing investigators and site personnel
- Responds to requests for information related to study indications, disease state and therapeutic area, and presents/discusses scientific/clinical data
- Attends medical conferences collecting and reporting relevant, scientific, clinical, & competitive intelligence
- Ensures company policies, procedures, principles and financial controls are maintained with integrity and professionalism is displayed internally and externally
Preferred Qualifications
- Established relationships with KOLs and institutions focused on Hematologic Malignancies
- Drug launch experience